Sensitivity and specificity analysis of select biomarker panel in diagnosing RA
| Number of positive biomarkers* | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|
| ≥1 markers | 70 | 50 | 47 | 73 |
| ≥2 markers | 60 | 85 | 72 | 77 |
| ≥3 markers | 57 | 92 | 81 | 77 |
| ≥4 markers | 57 | 96 | 90 | 78 |
| ≥5 markers | 57 | 96 | 90 | 78 |
| CCP2 ELISA | 47 | ND | ND | ND |
Sera analysed PPVs were from patients with RA (n=30), SLE (n=23), PsA (n=9), gout (n=6) and healthy controls (n=10).
*Biomarker panel identified in online supplementary table S1.
CCP, cyclic citrullinated peptide; ND, not determined; NPV, negative predictive value; PPV, positive predictive value; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.